Arcutis Biotherapeutics, Inc. (ARQT)
28.26
+0.73
(+2.65%)
USD |
NASDAQ |
Nov 13, 16:00
28.26
0.00 (0.00%)
After-Hours: 19:59
Arcutis Biotherapeutics Enterprise Value : 3.333B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 3.333B |
| November 11, 2026 | 3.440B |
| November 10, 2026 | 3.315B |
| November 09, 2026 | 3.166B |
| November 06, 2026 | 3.084B |
| November 05, 2026 | 3.267B |
| November 04, 2026 | 4.155B |
| November 03, 2026 | 3.897B |
| November 02, 2026 | 3.803B |
| October 30, 2026 | 3.905B |
| October 29, 2026 | 3.893B |
| October 28, 2026 | 3.827B |
| October 27, 2026 | 3.856B |
| October 26, 2026 | 3.873B |
| October 23, 2026 | 3.796B |
| October 22, 2026 | 3.922B |
| October 21, 2026 | 3.880B |
| October 20, 2026 | 4.000B |
| October 19, 2026 | 3.883B |
| October 16, 2026 | 3.496B |
| October 15, 2026 | 3.531B |
| October 14, 2026 | 3.192B |
| October 13, 2026 | 3.152B |
| October 12, 2026 | 3.168B |
| October 09, 2026 | 3.214B |
| Date | Value |
|---|---|
| October 08, 2026 | 2.950B |
| October 07, 2026 | 2.910B |
| October 06, 2026 | 2.878B |
| October 05, 2026 | 3.033B |
| October 02, 2026 | 3.035B |
| October 01, 2026 | 3.051B |
| September 30, 2026 | 3.195B |
| September 29, 2026 | 3.235B |
| September 28, 2026 | 3.308B |
| September 25, 2026 | 3.256B |
| September 24, 2026 | 3.175B |
| September 23, 2026 | 3.188B |
| September 22, 2026 | 3.364B |
| September 21, 2026 | 3.136B |
| September 18, 2026 | 3.063B |
| September 17, 2026 | 3.198B |
| September 16, 2026 | 3.158B |
| September 15, 2026 | 2.828B |
| September 14, 2026 | 2.923B |
| September 11, 2026 | 2.875B |
| September 10, 2026 | 2.812B |
| September 09, 2026 | 2.869B |
| September 08, 2026 | 2.938B |
| September 04, 2026 | 2.877B |
| September 03, 2026 | 2.847B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.230B |
| ADMA Biologics, Inc. | 3.028B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 166.16M |
| Savara, Inc. | 870.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 8.801M |
| Revenue (Quarterly) | 143.92M |
| Total Expenses (Quarterly) | 135.12M |
| EPS Diluted (Quarterly) | 0.0643 |
| Gross Profit Margin (Quarterly) | 91.34% |
| Profit Margin (Quarterly) | 6.12% |
| Earnings Yield | 0.76% |
| Operating Earnings Yield | 0.93% |
| Normalized Earnings Yield | 0.7647 |